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The present studywas carried out to investigate the changes in oxidative and inflammatory status in streptozotocin-induced diabetic
rat’s kidneys and serum following treatment with Withania coagulans, a popular herb of ethnomedicinal significance. The key
markers of oxidative stress and inflammation such as inflammatory cytokines (IL-1𝛽, IL-6, and TNF-𝛼) and immunoregulatory
cytokines (IL-4 and IFN-𝛾) were increased in kidneys along with significant hyperglycemia. However, treatment of four-month
diabetic rats with Withania coagulans (10mg/kg) for 3 weeks significantly attenuated hyperglycemia and reduced the levels of
proinflammatory cytokines in kidneys. In addition,Withania coagulans treatment restored the glutathione levels and inhibited lipid
peroxidation alongwithmarked reduction in kidney hypertrophy.The present study demonstrates thatWithania coagulans corrects
hyperglycemia and maintained antioxidant status and reduced the proinflammatory markers in kidneys, which may subsequently
reduce the development and progression of renal injury in diabetes.The results of the present study are encouraging for its potential
use to delay the onset and progression of diabetic renal complications. However, the translation of therapeutic efficacy in humans
requires further studies.
1. Introduction
Diabetes, a rising epidemic throughout the world, has no
signs of abatement and remains one of the most challeng-
ing health problems. People with diabetes suffer from the
detrimental vascular which accounts for high morbidity
and mortality [1]. Among several vascular complications,
chronic renal failure and end stage renal diseases appear
first and often associated with metabolic and hemodynamic
alternations. The development and progression of diabetes
and associated vascular complications are largely precipitated
by chronic hyperglycemia-induced oxidative stress [2]. In
addition to oxidative stress, immune-mediated low grade
chronic inflammatory mechanisms have been demonstrated
to play a significant role in pathogenesis of renal injury
in long term diabetes [3]. Convincing number of studies
demonstrates that oxidative stress and immune inflammatory
processes intimately linked together causing renal damage
through multiple mechanisms [3–6].
Themanagement of diabetic renal complications is based
on the approaches to delay the development and progres-
sion by keeping strict control of blood pressure or plasma
glucose [7]. However, controlling the blood pressure and
plasma glucose levels to prevent the renal complications
is far from satisfactory [7]. This imperfection points to
the need for newer therapeutic agents that have potential
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to target these intimately linked cascade; oxidative stress-
inflammatory cytokine signaling and delay the progression
and development of renal complications in diabetes [7].
Therefore, in search of newer therapeutic agents, medicinal
plants considered as a major source of drug discovery from
natural origin have been extensively explored [1].
Subsequently, many plant-derived natural products have
the potential to be effective in diabetic renal complications
by attenuating oxidative stress and proinflammatory and
immunoregulatory cytokines [8–10]. The challenge is to
identify the most promising compounds and evaluate their
protective mechanism. The fruits of Withania coagulans
belonging tofamily Solanaceae have received considerable
attention for their benefits in chronic degenerative diseases
including diabetes.Theplant,Withania coagulans, commonly
known as Indian Rennet, vegetable rennet (English), Panir
dodi (Hindi), and Ning gu shui qie (Chinese), has been
reported to possess a variety of ethnomedicinal uses [11].
The extract has shown potential activities, namely, anticancer
[12], woundhealing [13], immunomodulating [14], antihyper-
glycemic [15], and hypolipidemic [16] activities.
Despite several reports of its benefits in diabetes [11,
15, 17–19] and considering its potential to target the com-
plex interplay of oxidative stress and inflammatory and
immunoregulatory cytokines in diabetic renal complication
it is worthwhile to study the effect of Withania coagulans in
kidneys of streptozotocin- (STZ-) induced diabetes. In order
to understand the mechanism, the present study examined
the effect ofWithania coagulans on antioxidant defense, lipid
peroxidation, and immunoregulatory and proinflammatory
cytokines.
2. Material and Methods
2.1. Chemicals. STZ, sodium citrate, citric acid, bovine
serum albumin, 5-sulfosalicylic acid (SSA), naphthalene
diamine dihydrochloride, sulphanilamide, phosphoric acid,
HEPES ((4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid), sucrose, 1,4-dithiothreitol (DTT), CHAPS 3-[(3-
Cholamidopropyl)dimethylammonio]-1-propanesulfonate,
sodium chloride, protease inhibitors, phenylmethylsulfonyl
fluoride (PMSF), tween 20, sodium nitrate, 3,3,5,5󸀠-Te-
tramethylbenzidine (TMB), glutathione (GSH) assay kit,
and all other required chemicals, if not specified, were
purchased from Sigma-Aldrich (Sigma Chemical Co., St.
Louis, MO, USA). All chemicals used in the present study
were of analytical grade. Malondialdehyde (MDA) assay
kit was purchased from Northwest Life Science Specialties
(WA, USA). Cytokines duo set ELISA kits were purchased
from R&D Systems (Minneapolis, MN, USA). EnzChek
myeloperoxidase (MPO) activity assay kit was purchased
from Life Technologies (NY, USA).
2.2. Animals andDiet. MaleWistar rats (230 to 250 g) bred in
the animal research facility of College ofMedicine andHealth
Sciences,UnitedArabEmiratesUniversity, AlAin,UAE,were
used. The animals were housed under standard laboratory
conditions (22 ± 2∘C and 65 ± 5% humidity) and maintained
on a 12-hour light/dark cycle. The animals had free access
to food and water and were fed commercially available
standard rat diet. A maximum of four rats were housed per
cage and acclimatized to the laboratory conditions prior to
the commencement of the experiment. The experimental
protocols were approved by the Institutional Animal Ethics
Committee of College of Medicine and Health Sciences
(IAEC CMHS), United Arab Emirates University, Al Ain,
UAE, and conducted according to the criteria outlined in
the guide for the care and use of laboratory animals by the
National Academy of Sciences.
2.3. Preparation of the Withania coagulans Aqueous Fruit
Extract. A standard protocol was followed for the extraction
of Withania coagulans. The fruits of Withania coagulans
(0.28 g/100mL) were soaked in distilled water overnight
followed by a mechanical dispersion using a sterile cotton
wood (Hardwood Products Company, Guilford, CT, USA)
and filtration through cheese cloth.The dose of 10mg/kg was
selected based on a dose response pilot study in our labora-
tory. A total of five doses (0, 10, 125, 625, and 1250mg/kg)
were screened to find out the optimal dose following a dose
response curve in a postprandial glucose test based dose
response study. Five groups of six STZ diabetic rats each
were fasted overnight and used in the experiment. Group
I served as diabetic control and received vehicle (distilled
water only). Rats of groups II, III, IV, and V received doses
of 10, 125, 625, and 1250mg/kg, respectively, of aqueous fruit
extract suspended in distilled water. The level of baseline
blood glucose was measured at 0 hr, followed by an oral
administration of either distilled water (diabetic control
group) or Withania coagulans extract. The rats were allowed
to have free access to food and water.The blood samples were
collected from tail vein at 1, 2, 3, and 4 hrs after giving the
extract using anACCU-CHEKperforma glucometer. Among
the doses studied, the dose of 10mg/kg was found most
potent in exhibiting the antihyperglycemic activity (results
not shown). For further experiments, the dose of 10mg/kg
was chosen and a detailed study was performed.
2.4. Induction of Experimental Diabetes in Rats. A single dose
of 60mg/kg STZ was dissolved in freshly prepared citrate
buffer (pH 4.5; 0.1M) and injected intraperitoneally to induce
diabetes. The age matched control rats received an equal
amount of citrate buffer andwere used alongwith the diabetes
control group. Diabetes was confirmed by using Accucheck
performa glucometer (Roche Diagnostics, NSW, Australia),
after 48 hours of STZ injection. The rats having plasma
glucose levels of>350mg/dLwere considered as diabetics and
were used in the present study. The rats injected with STZ
provide a relatively inexpensive and easily accessible rodent
model that is not extremely obese and simulates the natural
history andmetabolic characteristics of patients with diabetes
mellitus [20].
2.5. Experimental Design. The rats were divided into three
experimental groups, each consisting of six rats. Group 1
served as nondiabetic controls group. The group 2 and 3
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Figure 1: Schematic diagram of the experimental groups and treatment protocol.
rats were four-month diabetic at the start of the experi-
ment. Group 2 served as STZ-induced diabetic group; group
3 served as diabetic group treated orally with Withania
coagulans (10mg/kg/day b.w. for 3 weeks). The schematic
representation of the experimental groups and treatment
procedure are presented in Figure 1. During the experimental
period, the body weight and blood glucose were determined
at regular intervals. The blood glucose level was measured
before treatment and after the 3-week treatment over a period
of 4 h. At the end of the experimental period, rats were euth-
anized and the kidneys were removed and processed for the
estimation of reduced glutathione (GSH), malondialdehyde
(MDA), nitric oxide (NO), and cytokines (IL-1𝛽, IL-4, IL-6,
TNF-𝛼, and IFN-𝛾) using the specific kits.
2.6. Preparation of Kidney Tissue Homogenate. The kidneys
were removed, weighed, washed in ice-cold PBS, and minced
into 2–5mm fragments followed by homogenization using a
polytron homogenizer (IKA Laboratory, Germany), with 5
volumes of ice-cold buffer containing 100mM HEPES, pH
7.5, 10% sucrose, 10mM DTT, 0.1% CHAPS, 150mM NaCl,
protease inhibitors tablet, and 1mM PMSF. The samples
were centrifuged at 10000×g for 10min and the obtained
supernatant was removed and stored at −80∘C until the
assessment of MPO activity and cytokines using ELISA kits.
2.7. Determination of Oxidative Stress Markers. The levels
of GSH and MDA were determined using commercially
available kits in serum and kidney. The level of NO was
measured only in kidney tissues.
2.8. Estimation of Reduced Glutathione (GSH). The GSH
content in serum and kidney homogenate was estimated
following manufacturer protocol of the assay kit. Briefly,
the measurement of GSH uses a kinetic assay in which
catalytic amounts (nmoles) of GSH cause a continuous
reduction of 5,5-dithiobis (2-nitrobenzoic acid) to nitroben-
zoic acid (TNB), and the glutathione disulfide (GSSG)
formed was recycled by glutathione reductase and NADPH.
The yellow color product, 5-thio-2-TNB, was measured
spectrophotometrically at 412 within 5min of 5,5-dithio-
bis(2-nitrobenzoic acid) addition, against a blank with no
homogenate. GSH concentration was expressed as 𝜇M of
GSH per milligram of tissue or per 0.01mL of serum.
2.9. Estimation of Malondialdehyde (MDA). The lipid perox-
idation product, MDA, in the kidney homogenate from each
group was measured using the MDA assay kit. Briefly, the
assay is based on the reaction of MDA with thiobarbituric
acid (TBA) to form aMDA-TBA adduct that absorbs strongly
at 532 nm. Briefly, the deproteinated tissue sample was
added to 1M phosphoric acid and butylated hydroxytoluene
in ethanol and then the mixture was heated at 60∘C for
60min.The suspension was cooled to room temperature and
centrifuged at 10000×g for 2-3min and the pink colored
supernatant was taken for spectroscopic measurements at
532 nm for the assay of MDA. The concentration of MDA
was expressed as 𝜇M per 10 milligram of tissue or per 0.1mL
serum.
2.10. Assay of Myeloperoxidase (MPO) Activity. The chlorina-
tion assay forMPO activity in serum and kidney homogenate
(ng/mg tissuewet weight) was performed in amicrotiter plate
using the EnzChekMPOactivity assay kit. Briefly, 50𝜇Lof 2×
3󸀠-(p-aminophenyl) fluorescein working solution was added
to 50𝜇L of sample. The reaction mixture was then incubated
in the dark at 37∘C for 20min. The fluorescence intensity of
each sample was recorded at 485 nm excitation and 530 nm
emission on a Perkin Elmer luminescence spectrofluorome-
ter.
2.11. Estimation of Nitric Oxide (NO). Accumulation of
nitric oxide was used to determine the production of NO
according to the Griess reagent (0.2% naphthylene diamine
dihydrochloride and 2% sulphanilamide in 5% phosphoric
acid) method. Briefly, 100 𝜇L of sample was mixed with
an equal volume of Griess reagent and incubated at room
temperature for 10–15min. The absorbance at 492 nm was
measured in an automated microplate reader (Tecan Group
Limited, Männedorf, Switzerland). The nitrite concentration
was quantitated using NaNO
2
as standard and was expressed
as micromolar concentrations of NO per mg tissue.
2.12. Determination of Proinflammatory Cytokines in Kidney.
Enzyme immunoassay of IL-1𝛽, IL-4, IL-6, TNF-𝛼, and IFN-
𝛾 in kidney homogenate was performed by using commer-
cial sandwich R&D duoset ELISA kit (Minneapolis, USA).
Briefly, the wells of a 96-well microtiter plate were coated
with respective primary antibody in phosphate buffer saline
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Table 1: Effect ofWithania coagulans on weight changes of body and kidney to body weight ratio. Twenty-one-day treatment withWithania
coagulans extract caused a significant improvement in the body weight and kidney to body weight ratio compared to diabetic controls.
Groups Body weight (gms) Kidney weight: body weight
Before treatment During treatment
Nondiabetic controls 368.166 ± 17.20 419.33 ± 22∗∗∗ 0.0029 ± 0.00012
Diabetic controls 266.4 ± 5.61 259.2 ± 5.39∗∗∗ 0.00469 ± 0.00017∗∗∗
W. coagulans treated 269.57 ± 7.09 292 ± 12.49∗∗,# 0.00408 ± 0.000084∗∗∗,#
Results are means ± SEM; 𝑛 = 6 rats; ∗∗𝑃 < 0.01, ∗∗∗𝑃 < 0.001 from nondiabetic controls; #𝑃 0.05 from diabetic controls.
(PBS), (100 𝜇L/well), overnight at room temperature, washed
with phosphate-buffered saline containing 0.05% Tween-20
(PBST), and then blocked with 1% bovine serum albumin
in PBS for one hour. After washing, plates were incubated
with serum, kidney homogenates, and respective standards
for 2 hours. After washing with PBST, a detection antibody
was added for 2 hours and 100 𝜇L of HRP was added for
half an hour, after the washing. The TMB-ELISA substrate
was added and the color intensity read at 450 nm with a
microplate reader (Tecan Group Ltd., Männedorf, Switzer-
land). Cytokines levels were expressed as pg per milligram of
tissue wet weight and per mL of serum.
2.13. Statistical Analysis. Data was analyzed statistically using
SPSS 19.0 software. The means of the data are presented with
the standard error mean (SEM). The results were analyzed
using one-way ANOVA to determine the significance of the
mean between the groups.Values of𝑃 < 0.05were considered
significant.
3. Results
3.1. Effect of Withania coagulans on Body Weight and Kidney
to Body Weight Ratio. Table 1 shows the changes in body
weight and the ratio of kidney/body weight in different
experimental groups. There was a significant (𝑃 < 0.001)
decrease in the body weight of rats administered STZ in
comparison with rats of nondiabetic control group. Diabetic
rats treated with Withania coagulans show a significant
(𝑃 < 0.05) improvement in body weight when compared
to diabetic control rats. Ratio of kidney/body weight is an
index of renal hypertrophy and a significant (𝑃 < 0.001)
increase in kidney/body weight indicates renal injury in
STZ administered rats. However, treatment with Withania
coagulans to the diabetic rats has significantly (𝑃 < 0.05)
reduced renal hypertrophy as evidenced by reduction of
kidney/body weight when compared to the diabetic control.
3.2. Effect of Withania coagulans on Blood Glucose, BUN, and
Creatinine. The changes in the level of blood glucose and
serum insulin in the rats of different experimental groups
are represented in Figure 2. A significant (𝑃 < 0.001)
and persistent rise in plasma glucose level was observed in
STZ administered rats as compared with nondiabetic control
group. However, a significant (𝑃 < 0.001) reduction was
observed in the plasma glucose level of diabetic rats treated






































Figure 2: Effect of Withania coagulans on blood glucose level. The
diabetic treated rats showed significant decrease in blood glucose
levels compared to diabetic controls. Results aremeans± SEM; 𝑛 = 6
rats; ∗𝑃 < 0.05, ∗∗𝑃 < 0.01, ∗∗∗𝑃 < 0.001 fromnondiabetic controls;
##𝑃 < 0.01, from diabetic controls.
The BUN and creatinine levels were not different between the
different groups (results not shown).
3.3. Effect of Withania coagulans on Glutathione. Animals
administered STZ showed a significant (𝑃 < 0.05) decrease
in the serum GSH level when compared to the nondiabetic
control group (Figure 3(a)). However, no significant change
in kidney GSH level was observed in diabetic rats when
compared to the nondiabetic control group. Treatment with
Withania coagulans extract significantly (𝑃 < 0.05) induced
the level of GSH, both in serum and in kidney of diabetic rats
when compared to diabetic control group (Figure 3(a)).
3.4. Effect of Withania coagulans Lipid Peroxidation. The rats
administered STZ showed a significant increase in the MDA
levels of serum (𝑃 < 0.05) and kidney (𝑃 < 0.001) as
compared to the nondiabetic control group (Figure 3(b)).
However, treatment withWithania coagulans has not reduced
the level ofMDA in serum and showed a slight nonsignificant
decrease in the kidney compared to diabetic control group
(Figure 3(b)).
3.5. Effect of Withania coagulans on MPO Activity. Amodest
but insignificant increase in MPO levels in kidney of the
diabetic control group was observed when compared to non-
diabetic control group (Figure 3(c)).However, treatmentwith










































































Figure 3: Effect ofWithania coagulans on serum and kidney levels of (a) GSH, (b) MDA, and (c) MPO. Results are means ± SEM; 𝑛 = 6 rats;
∗























Figure 4: Effect of Withania coagulans on levels of NO in kidney.
Results are means ± SEM; 𝑛 = 6 rats; #𝑃 0.05 from diabetic controls.
Withania coagulanswas found todecrease MPO levels in kid-
ney as compared to the diabetic control group (Figure 3(c)).
The decrease in MPO levels was not significant in any group.
3.6. Effect of Withania coagulans on Nitric Oxide. A modest
nonsignificant decrease in NO levels in kidney of the diabetic
control group was observed when compared to nondiabetic
control group (Figure 4). However, treatment withWithania
coagulans has significantly (𝑃 < 0.05) increased theNO levels
in kidney as compared to the diabetic control (Figure 4).
3.7. Effect of Withania coagulans on Proinflammatory Cytoki-
nes. Figures 5(a)–5(c) represent the levels of kidney proin-
flammatory cytokines such as IL-1𝛽, IL-6, and TNF-𝛼 of
different experimental groups: nondiabetic control, diabetic
control, and Withania coagulans treated. There was a signif-
icant increase in the level of IL-1𝛽 (𝑃 < 0.001), IL-6 (𝑃 <
0.001), and TNF-𝛼 (𝑃 < 0.05) in kidneys of STZ-induced
diabetic rats when compared to nondiabetic control group. A
significant decline in the kidney levels of IL-1𝛽 (𝑃 < 0.05),
IL-6 (𝑃 < 0.05), and TNF-𝛼 (𝑃 < 0.01) was observed
on treatment with Withania coagulans when compared to
diabetic control.
3.8. Effect of Withania coagulans on Immunoregulatory
Cytokines. The levels of IL-4 and IFN-𝛾 in kidneys of differ-
ent experimental groups are presented in Figure 6. Though
the change in IFN-𝛾 levels was not altered significantly, a sig-
nificant (𝑃 < 0.05) increase in the IL-4 level was observed in
STZ-induced diabetic rats when compared to the nondiabetic
control group. However, treatment with Withania coagulans
extract has significantly reduced the levels of IL-4 (𝑃 < 0.05)
and IFN-𝛾 (𝑃 < 0.01) in kidneys as compared to diabetic rats.
4. Discussion
In the present study, STZ-injected rats show significant
rise in plasma glucose level along with decrease in serum
insulin and body weight and increase in kidney weight in
comparison with nondiabetic control rats, indicating the
development of diabetes as characterized by chronic and
persistently elevated plasma glucose level. Decreased body
weight in STZ-induced diabetic rats is believed to be due



















































































Figure 5: Effect ofWithania coagulans on kidney levels of (a) IL-1𝛽, (b) IL-6, and (c) TNF-𝛼. Diabetic controls showed significantly elevated
kidney IL-1𝛽 (a), IL-6 (b), and TNF-𝛼 (c) cytokines levels, compared to nondiabetic controls. Withania coagulans treatment significantly
decreased the IL-1𝛽 (a), IL-6 (b), and TNF-𝛼 (c) compared to diabetic controls. Results are means ± SEM; 𝑛 = 6 rats; ∗𝑃 < 0.05, ∗∗∗𝑃 < 0.001






















































Figure 6: Effect ofWithania coagulans on kidney levels of (a) IL-4 and (b) IFN-𝛾.Withania coagulans treatment significantly decreased the
kidney IL-4 and IFN-𝛾 compared to diabetic controls. Results are means ± SEM; 𝑛 = 6 rats; ∗𝑃 < 0.05, ∗∗∗𝑃 < 0.001 from nondiabetic
controls; #𝑃 0.05, ##𝑃 < 0.01 from diabetic controls.
to dehydration, breakdown, and catabolism of fats and pro-
teins. Increased catabolic reactions after STZ administration
leads to muscle wasting and decreased body weight. STZ
induces diabetes by selectively destroying insulin producing
pancreatic endocrine cells and damages kidney similar to
early stage diabetic nephropathy [20, 21].This is in agreement
with various other observations that STZ-induced animals
exhibit diabetic renal complications [8, 9, 22]. However, treat-
ment with Withania coagulans restored body weight, kidney
weight, and reduced hyperglycemia, as well as enhancing
survival and general body growth of diabetic rats. Ratio of
kidney/body weight is an index of renal hypertrophy and
a significant increase in kidney/body weight indicates renal
injury in STZ administered rats. However, treatment with
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Withania coagulans to the diabetic rats has markedly reduced
renal hypertrophy as evidenced by reduction of kidney/body
weight when compared to the diabetic control. These results
demonstrate that the extract of Withania coagulans exhibits
antihyperglycemic effects through modulation of insulin and
related enzyme activities in consonance with other studies
demonstrated antihyperglycemic as well as protective effect
in other organs apart from kidneys [15–17].
Pathogenic mechanisms underlying the progressive renal
diseases in diabetics are known to be multifactorial including
oxidative stress, inflammation, and immune-dysfunction [5,
6]. Oxidative stress ultimately triggers inflammation and
modulates immunologic cascade in progression of renal
damage from genesis to progression [2, 3]. Hyperglycemia-
induced oxidative stress and inflammation unleash a cascade
of events that affect cellular proteins, gene expression, and cell
surface receptor expression, ultimately resulting in progres-
sive pathologic changes in diabetic kidneys [4]. To counteract
oxidative stress, the first line of defense against reactive
oxygen species (ROS) is GSH, an intracellular nonprotein
thiols compound, which also participate in second line
of defense as a substrate or cofactor for GSH-dependent
enzymes to detoxify ROS generated toxic byproducts and
prevent propagation of free radicals [23]. In the present
study, decreased levels of GSH in serum of STZ-injected
rats might be explained by depletion or consumption of
GSH in removing the hyperglycemia generated peroxides.
Following treatment with Withania coagulans,the improve-
ment in GSH level demonstrates its antioxidant activity in
agreement with other studies whereWithania coagulans was
shown to ameliorate oxidative stress [15–17]. Although no
significant change in renal GSH levels was observed in the
STZ administered rats, a significant rise in kidney GSH levels
was obtained following treatment with Withania coagulans
indicating increased production of GSH.
Furthermore, ROS, by impairing antioxidant defense,
renders the kidneys more susceptible to lipid peroxidation.
ROS induced lipid peroxidation is a marker of cellular oxida-
tive damage and is an important pathogenic event in renal
injury [24]. In our study, increased level of lipid peroxidation
product, MDA, clearly indicates oxidative stress in diabetic
kidneys. Following treatment with Withania coagulans,the
inhibition of lipid peroxidation as evidenced by decreased
albeit not significant MDA levels in kidney demonstrates
the antioxidant effect of Withania coagulans in agreement
with previous studies which showed its antilipid peroxidation
activity [15–17]. In addition to reduction of hyperglycemia,
the ability of Withania coagulans to prevent GSH depletion
and lipid peroxidation seems to be advantageous to mitigate
the oxidative stress and may delay the development and
progression of renal complications in diabetes.
In addition, change in MPO activity has been demon-
strated to play role in degenerative and immunologic changes
of the kidney [25]. In this study, we did not observe a
significant change in MPO activity. Changes in renal NO
levels have been linked to the pathogenesis of diabetes and
associated complications [26]. The complex oxidative milieu
in diabetes triggers several pathophysiologic mechanisms
that simultaneously stimulate or suppress NO production at
a given stage of the disease. Many studies demonstrated that
decrease in renal NO levels are partly results of enhanced
oxidative stress and partly of decreased NOS expression [27].
However, treatment of diabetic rats withWithania coagulans
significantly increased NO levels in the kidneys. This effect is
supported by the reduction of oxidative stress and could be
ascribed to the induction of NOS following a counterbalance
of NOS activity under the oxidative burst in accordance with
previous other studies [21, 24].
Recent studies have shown that long-term, innate
immune system activation resulting in chronic low grade
inflammation is associated with the risk of developing renal
complications, implying that immunologic and inflammatory
mechanisms play a significant role in disease development
and progression [4–6]. Studies suggest that proinflammatory
cytokines (IL-1𝛽, IL-6, and TNF-𝛼) and IFN-𝛾 (Th1) and
IL-4 (Th2) act as pleiotropic polypeptides that are inde-
pendently associated and exert an important diversity of
actions in diabetic kidneys from development to progression
[2, 6]. Both infiltrating immune cells (mainly monocytes and
macrophages) and renal resident cells (endothelial, mesan-
gial, dendritic, and epithelial) produce proinflammatory
cytokines such as IL-1𝛽, IL-6, and TNF-𝛼 [28]. The release
of these cytokines may lead to renal injury through several
mechanisms [6]. Being chemotactic in nature, the produced
chemokines recruit more inflammatory cells and activate
fibroblasts and matrix production, therefore, inducing the
development of diabetic renal complications [2, 6]. Further,
IFN-𝛾 secreted by activated T cells and NK cells in conjunc-
tion with proinflammatory cytokines activates macrophages
and stimulates chemokine production which result in patho-
logical lesions of diabetic renal diseases. Increased IL-1𝛽 in
kidney is known to increase the subsequent expression of
chemotactic factors and adhesion whereas increased IL-6
levels are known to alter endothelial permeability, induce
proliferation, and increase fibronectin expression [6, 9]. In
the present study, a significant increase in cytokine levels,
IL-1𝛽, IL-4, IL-6, and TNF-𝛼,, in kidneys of rats injected
STZ are in agreement with previous studies [21]. Following
treatment with Withania coagulans, significant reduction in
the level of these cytokines is clearly suggestive of its anti-
inflammatory effect in diabetic kidney. Thus, the attenuation
of proinflammatory cytokines and lipid peroxidation along
with diminution of hyperglycemia and improved antioxi-
dants by Withania coagulans treatment is clearly suggestive
of its beneficial effects in diabetic kidney.
Recent evidences in alternative medicine have encour-
aged that whole herb formulation is an effective therapeu-
tic modality in chronic diseases including diabetes due to
their multitudes of synergistic bioactivities and nutritional
properties [29]. The current concept has revealed a new class
of agents, known as adaptogens which increase resistance
of the organism to aversive stimuli threatening to perturb
internal homeostasis. The adaptogens have the potential to
reverse stress induced immunity deregulation and organ
dysfunction by sparing the antioxidants and modulating the
immune system [29]. The immunoregulatory cytokines play
an essential role in downmodulating adaptive and innate
immune responses leading to chronic inflammation [4].
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Several studies have demonstrated the adaptogenic activity
ofWithania species by inducing immune-surveillance [14]. In
the present study, the decreased levels of immunoregulatory
cytokines, IL-4 and IFN-𝛾 are strongly suggestive of the
immunomodulatory and associated adaptogenic potential of
Withania coagulans in consonance with therapeutic benefits
of adaptogenic medicines in chronic diseases [30]. Withania
described in Indian Ayurvedic medicine as Rasayana drugs
is believed to produce its positive health impact through
immune-enhancing, longevity promotion, and molecular
nutritive effect [29].
Based on the present study findings and supportive
data from ethnomedicinal, clinical, and preclinical studies
[11, 15, 17–19], Withania coagulans holds promise for its
potential in delaying the progression of renal complications
in diabetes. Being a natural agent and due to its time tested
use since ancient time is supportive of its relative safety. This
is encouraging for Withania coagulans to be used in pre-
vention and treatment of preventing renal complications in
diabetes. Coupledwithmultiple pharmacological effects such
as antihypertensive, hypolipidemic, hypoglycemic, immuno-
suppressive, antioxidant, anti-inflammatory, and adaptogenic
activity, Withania coagulans might be a good therapeutic
agent against renal complications of diabetes which involves
multifactorial aetiopathogenesis.
To conclude, the results of our study demonstrate that
treatment with Withania coagulans reduces the occurrence
of oxidative stress and inflammation and improves hyper-
glycemia owing to its synergistic and polypharmacological
properties. Further studies are encouraged for the transla-
tional application in humans.
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